The trial was conducted across over 120 centres in 12 nations, including Canada, and regions across Asia and Europe.

Imfinzi plus BCG induction and maintenance therapy showed a statistically and clinically meaningful improvement in DFS for ...

Phase III POTOMAC trial showed that adding Durvalumab (Imfinzi) to BCG induction and maintenance therapy significantly ...

May is Bladder Cancer Awareness Month and at Frontiers in Oncology, we are dedicated to spotlighting the groundbreaking discoveries transforming the ...

Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing ...

Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients ...

Dr. Nicolas Soputro, a research fellow at the Cleveland Clinic, presented on the use of a robotic transurethral device for bladder tumor resection. He began by emphasizing that transurethral resection ...

Recurrence in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer is common, and there have been a lack of alternative treatments to TURBT.

Three abstracts were presented from Photocure's U.S. Blue Light Cystoscopy with Cysview Registry, a large multicenter bladder cancer patient registry of real-world data, established by Photocure in ...

In the pivotal CREST clinical trial, sasanlimab in combination with Bacillus Calmette-Guérin met the primary endpoint of ...

Real-life cancer survivor story: A 50-year-old resident of Cheshire, who mistook his initial symptoms of bladder cancer to be a UTI, drank cranberry juice as a possible treatment after being diagnosed ...

A dad who thought he had a UTI was diagnosed with stage four bladder cancer and given 24 months to live. Dad-of-two Chris Cotton, 50, started experiencing what he believed were UTI symptoms in ...